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Purpose. We performed a retrospective study to determine the outcome of a modern cohort of patients with high-grade (Gleason
score ≥ 8) prostate cancer treated with radical prostatectomy, radiation therapy, or hormone therapy. Methods. We identiﬁed
404 patients in the South Texas Veteran’s Healthcare System Tumor Registry diagnosed with high grade prostate cancer between
1998 and 2008. Mean follow-up was 4.62 ± 2.61 years. End points were biochemical failure-free survival, overall survival,
metastasis-free survival, and cancer-speciﬁc survival. Results. 5-year overall survival for patients undergoing radical prostatectomy,
radiation therapy, and hormone therapy was 88.9%, 76.3%, and 58.9%, respectively. 5-year metastasis-free survival for patients
undergoing radical prostatectomy, radiation therapy, and hormone therapy was 96.8%, 96.6%, and 88.4%, respectively, and 5-
year cancer-speciﬁc survival was 97.2%, 100%, and 89.9%, respectively. Patients with a Gleason score of 10 and pretreatment
prostate-speciﬁc antigen > 20ng/mL had decreased 5-year biochemical failure-free and cancer-speciﬁc survival. Patients with a
pretreatment prostate-speciﬁc antigen > 20ng/mL had decreased 5-year overall survival. Discussion. Even for patients with high-
grade disease, the outcome is not as dire in the modern era regardless of primary treatment modality chosen. While there is room
for improvement, we should not have a nihilistic impression of how these patients will respond to treatment.
1.Introduction
In the modern era of prostate speciﬁc antigen (PSA) screen-
ing, thousands of men are diagnosed with prostate cancer
each year that would have previously escaped detection.
Of the estimated 218,000 American men diagnosed with
prostate cancer in 2010 [1], men with high-grade disease
(Gleason 8–10) are at greatest risk for adverse outcomes.
Gleason score has long been shown to correlate well with
risk for local extension, metastasis, and death [2]. While
clinicians generally agree that men with high-grade disease
require prompt therapy to limit disease-speciﬁc morbidity
and mortality, the best treatment for these men remains
controversial. As a result, they are treated with a variety of
diﬀerent options.
Radical prostatectomy (RP) and radiation therapy (RT)
remain the standard modalities for treatment of patients
with prostate cancer. Hormone therapy (HT) is used either
in combination with more deﬁnitive therapy or consid-
ered palliative treatment when used alone. Regardless of
treatment, patients with high-grade prostate cancer have
historically experienced poor outcomes. Prior studies have
shown poor survivorship rates for those treated with either
RP [3] or RT alone [4]. Patients who are surgical candidates
for radical prostatectomy are often younger and lack the
comorbidities of their counterparts receiving RT. These and2 ISRN Oncology
other confounders limit retrospective studies comparing
eﬃcacies of RP and RT. One study showed no signiﬁcant
diﬀerence in rates of PSA failure at 10 years in high-
risk patients treated with RP or RT [5]. Large prospective,
randomized studies are required to deﬁnitively compare
these two standards of treatment, but due to a variety of
obstacles, they remain notably absent from the current
literature.
Any discussion on treatment modalities for high-grade
prostate cancer would be incomplete without consideration
of HT. Though traditionally considered a palliative treat-
ment, a small number of studies have suggested primary HT
aﬀects meager improvements in either overall survival [6]o r
prostate cancer-speciﬁc survival [7]. Further investigation of
HT is warranted to elucidate its role as singular therapy and
its contribution to combined therapy with RP and RT.
There are few currently published studies examining
treatment outcomes for an entire cohort of patients with
high-grade disease from a single institution. Thus, in this
retrospective analysis of patients diagnosed with Gleason 8–
10 prostate cancer in the South Texas Veteran’s Health Care
System,weaimtoexaminetheeﬀectsofpretreatmentdisease
characteristicsandinitialtreatmentmodalityonbiochemical
failure-free survival (BFFS), metastasis-free survival (MFS),
cancer-speciﬁc survival (CSS), and overall survival (OS) in
the modern era. It would be unrealistic in this retrospective
review to directly compare outcomes between patients
receiving RP, RT, and HT. Most studies report these cohorts
separately, but we think that it is informative to look at
the outcome for the entire high-risk population across the
various treatment modalities. We hypothesize that high-
grade patients from this modern cohort will have less failure
and better survival than those previously reported.
2. Methods
After receiving approval from the institutional review board,
we reviewed all patients in the South Texas Veteran’s Health-
care System Tumor Registry diagnosed with prostate cancer
between January 1, 1998, and December 31, 2008, capturing
404 patients with Gleason score ≥ 8 on biopsy or on
radical prostatectomy pathology. Sixty-one surgical patients
had a biopsy Gleason score < 8b u tw e r ef o u n dt oh a v e
Gleason 8–10 disease on RP pathology. Statistical analysis
was performed both with and without the inclusion of
these patients, and their inclusion did not lead to signiﬁcant
diﬀerences in outcome measure comparison.
Patient information recorded from the medical record
included age at diagnosis, race, PSA immediately prior to
diagnosis, information from the original biopsy report such
as Gleason score as determined by the original attending
pathologist, percentage of positive cores, and whether posi-
tive cores came from one or both sides of the prostate. The
primary treatment of prostate cancer was recorded as RP,
RT, or HT. Furthermore, surgical pathology characteristics,
as interpreted and recorded by the original attending pathol-
ogist, were recorded including presence of positive lymph
nodes, positive seminal vesicles, extracapsular extension, and
positive surgical margins. Finally, the use of any adjuvant or
neoadjuvant treatment including HT, RT, or chemotherapy
was recorded. Patients were excluded from analysis if they
had metastatic disease at the time of diagnosis as identiﬁed
by bone scan, computed tomography scan, or magnetic
resonance imaging. Patients were also excluded from analysis
iftheydidnotreceivetreatmentfortheirprostatecancerorif
they were lost to follow up before posttreatment PSA values
could be obtained.
Biochemical failure was deﬁned diﬀerently depending on
the primary treatment. For surgical patients, biochemical
failure was deﬁned by PSA ≥ 0.2ng/mL followed by a
conﬁrmatory PSA value ≥ 0.2ng/mL [8]. For radiation pa-
tients, biochemical failure was deﬁned by a PSA rise
2.0ng/mL above the nadir [9]. Patients receiving RP or
RT were also considered to have failed on the date salvage
treatmentwasinitiated.ForpatientsreceivingHT,failurewas
deﬁned by the development of metastasis or the initiation of
another treatment modality. Patients who had only received
a luteinizing hormone releasing hormone (LHRH) agonist
were not recorded as failing with a rising PSA until either
their PSA continued to rise after additionally having received
an antiandrogen, or they failed another way. The choice of
initial treatment was determined by the treating physician
after receiving informed consent from the patient. Reasons
a patient may receive HT as opposed to one of the localized
treatment modalities, RT or RP, include, but are not limited
to, poor candidacy for surgery or radiation due to medical
comorbidities, bulk of disease, or patient preference.
2.1. Statistical Methods. Continuously distributed data were
summarized with the sample size, mean, and standard
deviation (SD), and categorical data were described with
counts and percentages. Data were grouped by primary
treatment modality, RP, RT, or HT. Groups were contrasted
on continuously distributed outcomes with Kruskal-Wallis
tests. The signiﬁcance of associations between categorical
outcomesandprimarytreatmentwasassessedwithPearson’s
chi-square test. Treatment categories were contrasted with
regard to biochemical failure-free, metastasis-free, cancer-
speciﬁc, and overall survival using a logistic regression
model adjusted for age, Gleason score, pretreatment PSA,
and positive cores. All statistical testing was 2-sided with a
signiﬁcance level of 5%. SAS Version 9.2 for Windows (SAS
Institute, Cary, North Carolina) was used throughout.
3. Results
Included for analysis were 404 patients with high-grade
prostate cancer and a mean follow-up time of 4.62 ±
2.61 years. Not unexpectedly, the patient characteristics for
the various treatment modalities varied (Table 1). Patients
receiving RP were signiﬁcantly younger than those receiving
RT or HT (64.6 ± 7.2y e a r sc o m p a r e dw i t h7 0 .9 ± 8.4a n d
77 ± 8.1, resp.; P<0.001). Patients in the treatment groups
did not signiﬁcantly diﬀer in terms of race or Gleason score,
but surgical patients had a lower mean pretreatment PSA
than those receiving RT or HT (10.3±11.9ng/mL comparedISRN Oncology 3
Table 1: Comparison of patient demographics and pretreatment features.
Surgery Radiation Hormone therapy Total P value
Age <0.0011
N 216 59 129 404
Mean (SD) 64.6 (7.2) 70.9 (8.4) 77 (8.1) 69.5 (9.5)
Race, N (%) 0.482
White 161 (74.5) 40 (67.8) 92 (71.3) 293 (72.5)
Black 14 (6.5) 7 (11.9) 16 (12.4) 37 (9.2)
Other 3 (1.4) 0 (0) 1 (0.8) 4 (1)
Unknown 38 (17.6) 12 (20.3) 20 (15.5) 70 (17.3)
Total 216 59 129 404
Gleason score, N (%) 0.372
8 84 (54.2) 33 (55.9) 63 (48.8) 180 (52.5)
9 67 (43.2) 22 (37.3) 57 (44.2) 146 (42.6)
10 4 (2.6) 4 (6.8) 9 (7) 17 (5)
Total3 155 59 129 343
PSA at diagnosis (ng/mL) <0.0011
N 208 57 126 391
Mean (SD) 10.3 (11.9) 15.5 (27.1) 48.2 (79.4) 23.3 (50)
Fraction of positive cores <0.0011
N 214 59 126 399
Mean (SD) 50% (30%) 40% (30%) 60% (30%) 50% (30%)
1Kruskal-Wallis Test.
2Pearson’s Chi-Square Test.
361 surgical patients had a Gleason score of <8 on biopsy but ≥8 on radical prostatectomy pathology and thus were included for analysis.
with 15.5 ± 27.1a n d4 8 .2 ± 79.4, resp.; P<0.001). Patients
receiving HT also had a greater percentage of positive biopsy
cores than those receiving RP or RT (60% positive compared
with 50% and 40%, resp.; P<0.001) (Table 1). Overall,
patients receiving androgen ablation were older and had
bulkier cancers than those undergoing radiation therapy or
surgery.
Gleason score and pretreatment PSA were associated
with signiﬁcant diﬀerences in outcomes (Table 2). Patients
with increasing Gleason score had decreasing 5-year BFFS
and CSS, and patients with increasing pretreatment PSA had
decreasing 5-year OS, BFFS, and CSS. Patients undergoing
surgery had a signiﬁcant better overall survival, even after
adjusting for age, Gleason score, pretreatment PSA, and
percentage of positive cores. For the entire cohort, the 5-
year overall survival, metastasis-free survival, and cause-
speciﬁc survival were 77.5%, 94.1%, and 95.3%, respectively
(Table 3). Importantly, the metastasis-free and cause-speciﬁc
survival at 5 years were favorable across all the treatment
modalities. Overall survival probabilities are shown via a
Kaplan-Meier curve in Figure 1.
4. Discussion
Most currently published studies report long-term failure
and survival concerning patients diagnosed from the 1970s
to early 1990s. Though the extended follow-up aﬀorded
to these earlier studies allows for better characterization
of the long natural history of prostate cancer, advances in
surgical, radiation, and hormone therapy have led some
to wonder whether previously published survival estimates
are applicable to modern high-risk patients. Ours is one of
the largest modern cohorts including patients with high-
grade prostate cancer treated with RP, RT, or HT at a single
institution.
Overall, the patients in the entire cohort did surprisingly
well with a low rate of metastatic disease and cancer death.
Speciﬁcally, the 5-year rate of metastatic disease and cancer
death was <10%. There are really no comparative studies like
oursthatlookattheexperienceacrossthediﬀerenttreatment
modalities, but given the diﬀerences in patient selection, the
patients have done very similarly. It is interesting to further
evaluate each of the three treatment cohorts.
4.1. RP for High-Grade Prostate Cancer. For surgical patients
in our series, 5-year CSS was 97.2%. This is signiﬁcantly
more optimistic than previous high-grade prostate cancer
surgicalseriesreporting 10-yearCSSranging from67to85%
[3, 10–13].
Lau et al. from the Mayo Clinic reported BFFS, OS, and
CSS of 36%, 67%, and 85%, respectively, in a cohort of 407
patients with pathologic Gleason score ≥ 8 who underwent
RP from 1987 to 1996 [3]. In addition to the time period of
diagnosis, diﬀerences exist between these patients and those
in our series. Patients in Lau’s series had a higher percentage
of lymph node positive disease (27% versus 4.6% in our4 ISRN Oncology
Table 2: Comparison of outcome measures by pretreatment features and primary treatment.
Outcome measures
5-year OS P value1 5-year BFFS P value1 5-year CSS P value1
Gleason score
8 77.2% 0.71 75.6% <0.001 96.1% 0.001
9 74% 58.2% 95.9%
10 70.6% 41.2% 76.5%
Pretreatment PSA (ng/mL)
<10 80.7% 0.002 72.1% 0.001 98% <0.001
10–20 83.3% 61.1% 100%
>20 63.6% 51.1% 84.1%
Extent of disease at diagnosis
Unilateral 79.7% 0.53 67.8% 0.54 97.2% 0.28
Bilateral 77% 64.9% 95%
Percentage of positive cores
<50% 79.8% 0.30 71.3% 0.02 95.7% 0.69
≥50% 75.5% 60.6% 94.9%
Months from diagnosis to treatment
<3 76.5% 0.08 62.6% 0.29 94.2% 0.43
3–12 81.6% 70.2% 97.2%
>12 60% 70% 95%
1OS: Overall Survival; BFFS: Biochemical Failure-Free Survival; MFS: Metastasis-Free Survival; CSS: Cancer-Speciﬁc Survival.
2Pearson’s Chi-Square test.
series). Likely due to the advanced pathologic stage, 45% of
patients in Lau’s series received adjuvant treatment, whereas
only 10.2% of patients in our series received adjuvant,
concurrent, or neoadjuvant RT, HT, or chemotherapy.
More recently, Tewari et al. published long-term survival
outcomes on a cohort of 453 patients ≤ 75 years old with
high-grade prostate cancer treated with RP, RT, HT, or
active surveillance between 1980 and 1997, 119 of whom
underwent RP [14]. Using propensity risk analysis, Tewari
et al. reported a risk of cancer-speciﬁc death for surgical
patients that was 49% lower than patients receiving RT
and sixty-eight percent lower than patients receiving HT
or active surveillance (P = 0.53 and < 0.001, resp.).
Though unadjusted survival analysis suggested that patients
undergoing RP and RT had better CSS than those receiving
HT, after adjusting the logistic regression model for age,
Gleason score, and pretreatment PSA, our data showed no
signiﬁcant diﬀerence in 5-year CSS for patients undergoing
RP, RT, and HT (97.2%, 100%, and 89.9%, resp.; P = 0.91)
(Table 3). Overall, our results support that patients with
high-risk prostate cancer can do well with surgery as the
primary approach.
4.2. RT for High-Grade Prostate Cancer. In our series, 5-year
CSS for RT patients was 100%. Roach et al. report a dismal
44% 10-year CSS in patients treated with RT alone pooled
from four prospective phase III randomized RTOG trials
between 1975 and 1992 [4]. In contrast, 50.8% of the RT
patients in our series received either adjuvant, concurrent,
or neoadjuvant HT. 68% of patients from the RTOG trials
received a total dose less than 70 Gray (Gy), and as most
patients were diagnosed before the PSA era, most presented
with T3 disease, and 36% of those with T1-T2 disease had
positive lymph nodes [4]. In our series, 66.1% received
external beam radiation therapy (EBRT) with a mean dose of
75.5Gy (range 68.4 to 77Gy), 5.1% received brachytherapy,
18.6% received EBRT + brachytherapy boost, and 10.2% had
incomplete records.
Kupelian et al. reported equivalent 5-year BFFS when
comparing RP, EBRT, brachytherapy, or combination of
EBRT and brachytherapy as long as the EBRT dose met
or exceeded 72Gy [15]. D’Amico et al. likewise found no
signiﬁcant diﬀerence in BFFS between RP and EBRT after
8y e a r s[ 5]. Beyer and Brachman reported improved 5-year
BFFS with EBRT compared to brachytherapy for high-grade
patients [16], but as only 3 patients in our series received
brachytherapy alone, we could not observe any diﬀerence.
Stock et al. recently published a contemporary case series
of 181 patients with Gleason scores 8–10 treated with 103Pd
implant, 45GyEBRT,and9monthsofHTbetween1994and
2006. With reported 8-year BFFS, OS, MFS, and CSS of 73%,
79%, 80%, and 87%, respectively, Stock et al. show similarly
optimistic outcomes for high-grade prostate cancer patients
treated with RT in the modern era [17].
Overall, our results support that patients with high-risk
prostate cancer can do well with radiation therapy as the
primary approach.
4.3. HT for High-Grade Prostate Cancer. T h e r ei sad e a r t ho f
publications in the current literature describing failure andISRN Oncology 5
Table 3: 5-year outcome measures by primary treatment.
Surgery Radiation Hormone therapy Total P1
5-year OS, % 88.9% 76.3% 58.9% 77.5% 0.01
5-year BFFS, % 54.2% 81.4% 77.5% 65.6% <0.001
5-year MFS, % 96.8% 96.6% 88.4% 94.1% 0.24
5-year CSS, % 97.2% 100% 89.9% 95.3% 0.8
1OS: Overall Survival; BFFS: Biochemical Failure-Free Survival; MFS: Metastasis-Free Survival; CSS: Cancer-Speciﬁc Survival.
2Based on a logistic regression model adjusted for age, Gleason score, pretreatment PSA, and positive cores.
0
0
2.5 5 7.5 10 12.5
Years
Initial
HT: hormone therapy
RP: radical prostatectomy
RT: radiation therapy
HT
RP
RT
130
215
59
88
168
39
41
80
15
16
38
1
5
14
0
0
0
0.2
0.4
0.6
0.8
1
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
+ Censored
Logrank P<0.0001
Figure 1: Overall survival by initial treatment category.
survival of patients treated primarily with HT, and the few
studies that do exist report OS of 13%–48% [6, 7, 18].
Lu-Yao et al. failed to show signiﬁcantly improved 10-
year OS when compared with conservative management
17.3% versus 15.3%, respectively, in patients with poorly
diﬀerentiated disease [7]. However, Studer et al. reported
improved OS, though no eﬀect on CSS or symptom onset,
when androgen ablation was initiated immediately rather
than being deferred in an EORTC trial enrolling patients not
suitable for deﬁnitive treatment [6].
Our data show a more favorable outcome for patients
treated with HT. This may be partly due to the fact that of
the 36 patients failing HT, 18 went on to receive additional
treatment (11 received RT, 6 received chemotherapy, 1
received salvage RP). Also, in some cases, patients failing an
LHRH agonist were simply observed with a rising PSA and
died before metastatic disease became manifest. To that end,
many of these patients were treated with androgen ablation
due to advanced age and comorbidities along with high PSA
worrisomeforundetectedmetastasis.Withamediansurvival
of only 3.7 years, many died of intercurrent disease.
Our results support that in elderly patients with a
projected short longevity, primary androgen ablation can
provide reasonable control even in patients with bulky high-
grade disease.
Overall, the principle strength of this study is the large
number of prostate cancer patients from a single institution
in the modern diagnostic and treatment era. Study limita-
tions include those inherent to any retrospective analysis.
Selection of treatment was at the discretion of the original
treating physician and factors such as age, comorbidities,
prostate size, and patient preference aﬀected candidacy for
surgery, radiation, or hormone therapy. Selection bias and
noncongruent deﬁnitions of biochemical failure prevent
eﬀective comparison between RP, RT, and HT treatment
groups. Additionally, a mean follow-up of 4.6 ± 2.7y e a r si s
notlongenoughtocapturealldeathsfromprostatecanceror
development of metastatic disease. Though all our patients
were diagnosed and followed within the Veterans Health
Care System, a central pathologic review was not performed,
and Gleason scores as well as other pathologic features were
recorded as interpreted by the original attending patholo-
gists. Still, even with these limitations, our patients have
done fairly well with what would be universally considered
signiﬁcant disease.
5. Conclusions
Historically, patients with a Gleason score of 8–10 have done
very poorly. However, in the modern era, regardless of the
initial treatment, the outcome is not as dire. Possible reasons
are less bulky tumors at diagnosis due to the advent of
routine PSA screening and increased awareness of prostate
cancer in the community, as well as improved surgical
and radiation techniques. Prospective, randomized phase
III studies comparing all primary treatment groups would
provide the best information with which we counsel our
high-grade patients about any diﬀerences in the various
treatment modalities. In the absence of such trials, this
retrospective review can help provide insight into what
patients could possibly expect from RP, RT, and HT in the
moderntreatmentera.Whilethereisroomforimprovement,
we should not have a nihilistic impression of how these
patients will respond to treatment.
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